LOGO
LOGO

Could Exagen Be A Stock To Consider In 2026?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Exagen Inc. (XGN) has been drawing attention in the healthcare diagnostics space with its focus on autoimmune disease testing. Recent preliminary 2025 results highlight record revenue, expanding test volumes, and a stronger cash position, underscoring the company's momentum as it continues to advance innovation in autoimmune diagnostics.

Based in San Diego County, the company works to improve clarity in clinical decision-making for complex conditions such as lupus, rheumatoid arthritis, and Sjögren's syndrome. Its flagship product, AVISE CTD, along with a suite of AVISE-branded tests, provides clinicians with tools to diagnose, monitor, and manage autoimmune diseases with greater accuracy.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.